Gene Review:
Dpml - dopamine loss
Mus musculus
- Influence of age and strain on striatal dopamine loss in a genetic mouse model of Lesch-Nyhan disease. Jinnah, H.A., Jones, M.D., Wojcik, B.E., Rothstein, J.D., Hess, E.J., Friedmann, T., Breese, G.R. J. Neurochem. (1999)
- Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. Dervan, A.G., Meshul, C.K., Beales, M., McBean, G.J., Moore, C., Totterdell, S., Snyder, A.K., Meredith, G.E. Exp. Neurol. (2004)
- In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization. Shen, Y.Q., Hebert, G., Su, Y., Moze, E., Neveu, P.J., Li, K.S. Brain Res. (2005)
- Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment. West, B.D., Shughrue, P.J., Vanko, A.E., Ransom, R.W., Kinney, G.G. Pharmacol. Biochem. Behav. (2006)
- The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum. Sanchez, V., Zeini, M., Camarero, J., O'Shea, E., Bosca, L., Green, A.R., Colado, M.I. J. Neurochem. (2003)
- Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses. Fornai, F., Giorgi, F.S., Alessandrì, M.G., Giusiani, M., Corsini, G.U. J. Neurochem. (1999)
- Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Thiruchelvam, M., McCormack, A., Richfield, E.K., Baggs, R.B., Tank, A.W., Di Monte, D.A., Cory-Slechta, D.A. Eur. J. Neurosci. (2003)
- Tetrahydrobiopterin deficiency and dopamine loss in a genetic mouse model of Lesch-Nyhan disease. Hyland, K., Kasim, S., Egami, K., Arnold, L.A., Jinnah, H.A. J. Inherit. Metab. Dis. (2004)
- GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. Schneider, J.S., Kean, A., DiStefano, L. J. Neurosci. Res. (1995)
- A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Colado, M.I., Camarero, J., Mechan, A.O., Sanchez, V., Esteban, B., Elliott, J.M., Green, A.R. Br. J. Pharmacol. (2001)
- Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. Fornai, F., Battaglia, G., Gesi, M., Giorgi, F.S., Orzi, F., Nicoletti, F., Ruggieri, S. Brain Res. (2000)
- gamma-Tocopherol attenuates MPTP-induced dopamine loss more efficiently than alpha-tocopherol in mouse brain. Itoh, N., Masuo, Y., Yoshida, Y., Cynshi, O., Jishage, K., Niki, E. Neurosci. Lett. (2006)
- Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats. Fornai, F., Torracca, M.T., Bassi, L., D'Errigo, D.A., Scalori, V., Corsini, G.U. Brain Res. (1996)
- Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Grandbois, M., Morissette, M., Callier, S., Di Paolo, T. Neuroreport (2000)
- MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. Sonsalla, P.K., Zeevalk, G.D., Manzino, L., Giovanni, A., Nicklas, W.J. J. Neurochem. (1992)